Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EBIO Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Eleven Biotherapeutics Stock (NASDAQ:EBIO) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Eleven Biotherapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume15.58 million shsAverage Volume2.86 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More… Receive EBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EBIO Stock News HeadlinesAtara Biotherapeutics Inc.September 4, 2024 | wsj.comFlagship Ventures Fund IV-Rx, L.P.'s Net WorthSeptember 1, 2024 | benzinga.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.December 21, 2024 | Darwin (Ad)7-Eleven Australia’s family owners sell for $1.71bDecember 2, 2023 | afr.comEleven councillors quit Labour Party as Keir Starmer refuses to back Gaza ceasefireNovember 11, 2023 | mirror.co.ukCalifornia mayor criticizes Prop 47 after 7-Eleven Sikh employees beat alleged thiefAugust 16, 2023 | foxnews.comFree Slurpees? Yes, here's how to get one today and Tuesday, 7-Eleven's 96th birthdayJuly 31, 2023 | usatoday.comChicago police close in on 7-Eleven robbery suspects in LawndaleApril 9, 2023 | cbsnews.comSee More Headlines EBIO Stock Analysis - Frequently Asked Questions How were Eleven Biotherapeutics' earnings last quarter? Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) issued its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. What other stocks do shareholders of Eleven Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Sesen Bio (SESN), TransEnterix (TRXDW) and Dynavax Technologies (DVAX). Company Calendar Last Earnings5/15/2018Today12/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EBIO CUSIPN/A CIK1485003 Webwww.elevenbio.com Phone(617) 444-8550FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EBIO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eleven Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eleven Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
